Lv6
2500 积分 2022-07-08 加入
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
5天前
已完结
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
5天前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
11天前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
1个月前
已完结
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
1个月前
已完结
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors
2个月前
已完结
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
2个月前
已完结
Imatinib-induced ulcerative colitis
2个月前
已完结
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
2个月前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
2个月前
已完结
皖公网安备34019202002308
